Dixieland — there’s an app for that
JACKSONVILLE, Fla. — Winn-Dixie Stores on Monday introduced a smart phone application for its customers that will help them locate the closest Winn-Dixie, allow them to view the weekly circular and sales for that specific store, and create and manage shopping lists that both sync with computers and can be shared with other users.
“Our customers are on the go more than ever and this new app will make their busy lives easier,” stated Mary Kellmanson, Winn-Dixie group VP marketing. “Using the new app in the store, you can check off items as you place them in your cart so you’ll never miss an item on your list. And you’ll always be organized — no more paper lists stuffed in pockets or purses, or left at home or in the car.”
The app is available for Droid and Apple’s iPhone smart phones as a free download through Apple iTunes, the Android Market or through links on Winn-Dixie’s website at WinnDixie.com/mobile/apps.
Weis extends saving program
SUNBURY, Pa. — Weis Markets last week announced it has lowered the prices on 2,400 staple items, effective Jan. 2, and that it will freeze the prices of these products for 90 days through April 2.
It is the company’s sixth round of its 90-day Price Freeze program over the past two years.
“Our 90-day Price Freeze program continues to make sense in a slow-growth economy impacted by high unemployment in most of the markets we serve,” stated David Hepfinger, Weis Markets president and CEO. “It has been a great program for our customers. Over the past two years, our Price Freeze program has helped our customers save more than $6 million and we hope to save them more money in 2011.”
FDA declines to approve Iluvien
ATLANTA — The Food and Drug Administration declined to approve a treatment for diabetic eye disease made by Alimera Sciences, the drug maker said Dec. 23.
In its complete response letter, the FDA requested additional safety and efficacy data for the drug, Iluvien (fluocinolone acetonide intravitreal insert), a treatment for diabetic macular edema, a problem that commonly affects people with diabetes.
The agency also reported that it had found problems with current good manufacturing practices during inspections in August and September 2010 of plants operated by two of Alimera’s third-party manufacturers. According to Alimera, the manufacturers are in the process of resolving the problems.
A complete response letter means that the FDA has finished reviewing an approval application for a drug but issues remain that preclude final approval.
“We appreciate the FDA’s efforts to complete a priority review of our NDA and look forward to working closely with the FDA toward approval of Iluvien for the treatment of DME,” said Dan Myers, Alimera president and CEO. “To expedite the process, we have requested a meeting with the FDA to clarify the path to regulatory approval.”